Navrogen Announces The Closing Of $3.2M Funding To Support Its Humoral Immuno-Oncology Platform Discovery Technologies And Preclinical Pipeline

Navrogen Contacts:

Investor Inquiries:              

Media Inquiries:

Nicholas Nicolaides            

Steve Kyriakos

610-660-1931                    

610-660-1927

[email protected]                      

[email protected]